Cargando…

Longer interval between neoadjuvant chemoradiotherapy and surgery is associated with improved pathological response, but does not accurately estimate survival in patients with resectable esophageal cancer

Neoadjuvant chemoradiotherapy (nCRT) has been shown to reduce tumor burden and achieve tumor regression in patients with esophageal cancer (ESC). However, the most beneficial time interval between the administration of nCRT and surgery remains unclear. Therefore, the aim of the present study was to...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jiaqi, Zeng, Xiaoxiao, Zhou, Xiaojuan, Xu, Yong, Ding, Zhenyu, Hu, Yang, Yuan, Yong, Chen, Longqi, Wang, Jin, Lu, You, Liu, Yongmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018328/
https://www.ncbi.nlm.nih.gov/pubmed/36936022
http://dx.doi.org/10.3892/ol.2023.13741
_version_ 1784907786369368064
author Liu, Jiaqi
Zeng, Xiaoxiao
Zhou, Xiaojuan
Xu, Yong
Ding, Zhenyu
Hu, Yang
Yuan, Yong
Chen, Longqi
Wang, Jin
Lu, You
Liu, Yongmei
author_facet Liu, Jiaqi
Zeng, Xiaoxiao
Zhou, Xiaojuan
Xu, Yong
Ding, Zhenyu
Hu, Yang
Yuan, Yong
Chen, Longqi
Wang, Jin
Lu, You
Liu, Yongmei
author_sort Liu, Jiaqi
collection PubMed
description Neoadjuvant chemoradiotherapy (nCRT) has been shown to reduce tumor burden and achieve tumor regression in patients with esophageal cancer (ESC). However, the most beneficial time interval between the administration of nCRT and surgery remains unclear. Therefore, the aim of the present study was to explore the association of the duration of time between nCRT and surgery with the prognosis of patients with ESC. Patients with ESC who received nCRT following surgical resection (n=161) were reviewed and divided into the prolonged time interval group (time interval ≥66 days) and the short time interval group (time interval <66 days), according to the median value. Subsequent analysis revealed that the prolonged time interval group achieved a higher pathological complete response (pCR) rate compared with the short time interval group (49.4 vs. 26.3%; P=0.003). Furthermore, multivariate logistic regression analysis showed that it was possible to independently estimate a higher pCR rate based on a prolonged time interval (odds ratio, 2.131; P=0.042). However, no association between a prolonged time interval and disease-free survival (DFS) was detected using Kaplan-Meier curves (P=0.252) or multivariate Cox regression (P=0.607) analyses. Similarly, no association was identified between a prolonged time interval and overall survival (OS; P=0.946) based on Kaplan-Meier curve analysis, and subsequent multivariate Cox regression analyses showed that the time interval also failed to independently estimate OS (P=0.581). Moreover, female sex (P=0.001) and a radiation dose ≥40 Gy (P=0.039) served as independent factors associated with a higher pCR rate, and the pCR rate was an independent predictor of favorable DFS (P=0.002) and OS (P=0.015) rates. In conclusion, the present study revealed that a prolonged time interval from nCRT to surgery was associated with a higher pCR rate, but it failed to estimate the survival profile of patients with ESC.
format Online
Article
Text
id pubmed-10018328
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-100183282023-03-17 Longer interval between neoadjuvant chemoradiotherapy and surgery is associated with improved pathological response, but does not accurately estimate survival in patients with resectable esophageal cancer Liu, Jiaqi Zeng, Xiaoxiao Zhou, Xiaojuan Xu, Yong Ding, Zhenyu Hu, Yang Yuan, Yong Chen, Longqi Wang, Jin Lu, You Liu, Yongmei Oncol Lett Articles Neoadjuvant chemoradiotherapy (nCRT) has been shown to reduce tumor burden and achieve tumor regression in patients with esophageal cancer (ESC). However, the most beneficial time interval between the administration of nCRT and surgery remains unclear. Therefore, the aim of the present study was to explore the association of the duration of time between nCRT and surgery with the prognosis of patients with ESC. Patients with ESC who received nCRT following surgical resection (n=161) were reviewed and divided into the prolonged time interval group (time interval ≥66 days) and the short time interval group (time interval <66 days), according to the median value. Subsequent analysis revealed that the prolonged time interval group achieved a higher pathological complete response (pCR) rate compared with the short time interval group (49.4 vs. 26.3%; P=0.003). Furthermore, multivariate logistic regression analysis showed that it was possible to independently estimate a higher pCR rate based on a prolonged time interval (odds ratio, 2.131; P=0.042). However, no association between a prolonged time interval and disease-free survival (DFS) was detected using Kaplan-Meier curves (P=0.252) or multivariate Cox regression (P=0.607) analyses. Similarly, no association was identified between a prolonged time interval and overall survival (OS; P=0.946) based on Kaplan-Meier curve analysis, and subsequent multivariate Cox regression analyses showed that the time interval also failed to independently estimate OS (P=0.581). Moreover, female sex (P=0.001) and a radiation dose ≥40 Gy (P=0.039) served as independent factors associated with a higher pCR rate, and the pCR rate was an independent predictor of favorable DFS (P=0.002) and OS (P=0.015) rates. In conclusion, the present study revealed that a prolonged time interval from nCRT to surgery was associated with a higher pCR rate, but it failed to estimate the survival profile of patients with ESC. D.A. Spandidos 2023-03-03 /pmc/articles/PMC10018328/ /pubmed/36936022 http://dx.doi.org/10.3892/ol.2023.13741 Text en Copyright: © Liu et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Liu, Jiaqi
Zeng, Xiaoxiao
Zhou, Xiaojuan
Xu, Yong
Ding, Zhenyu
Hu, Yang
Yuan, Yong
Chen, Longqi
Wang, Jin
Lu, You
Liu, Yongmei
Longer interval between neoadjuvant chemoradiotherapy and surgery is associated with improved pathological response, but does not accurately estimate survival in patients with resectable esophageal cancer
title Longer interval between neoadjuvant chemoradiotherapy and surgery is associated with improved pathological response, but does not accurately estimate survival in patients with resectable esophageal cancer
title_full Longer interval between neoadjuvant chemoradiotherapy and surgery is associated with improved pathological response, but does not accurately estimate survival in patients with resectable esophageal cancer
title_fullStr Longer interval between neoadjuvant chemoradiotherapy and surgery is associated with improved pathological response, but does not accurately estimate survival in patients with resectable esophageal cancer
title_full_unstemmed Longer interval between neoadjuvant chemoradiotherapy and surgery is associated with improved pathological response, but does not accurately estimate survival in patients with resectable esophageal cancer
title_short Longer interval between neoadjuvant chemoradiotherapy and surgery is associated with improved pathological response, but does not accurately estimate survival in patients with resectable esophageal cancer
title_sort longer interval between neoadjuvant chemoradiotherapy and surgery is associated with improved pathological response, but does not accurately estimate survival in patients with resectable esophageal cancer
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018328/
https://www.ncbi.nlm.nih.gov/pubmed/36936022
http://dx.doi.org/10.3892/ol.2023.13741
work_keys_str_mv AT liujiaqi longerintervalbetweenneoadjuvantchemoradiotherapyandsurgeryisassociatedwithimprovedpathologicalresponsebutdoesnotaccuratelyestimatesurvivalinpatientswithresectableesophagealcancer
AT zengxiaoxiao longerintervalbetweenneoadjuvantchemoradiotherapyandsurgeryisassociatedwithimprovedpathologicalresponsebutdoesnotaccuratelyestimatesurvivalinpatientswithresectableesophagealcancer
AT zhouxiaojuan longerintervalbetweenneoadjuvantchemoradiotherapyandsurgeryisassociatedwithimprovedpathologicalresponsebutdoesnotaccuratelyestimatesurvivalinpatientswithresectableesophagealcancer
AT xuyong longerintervalbetweenneoadjuvantchemoradiotherapyandsurgeryisassociatedwithimprovedpathologicalresponsebutdoesnotaccuratelyestimatesurvivalinpatientswithresectableesophagealcancer
AT dingzhenyu longerintervalbetweenneoadjuvantchemoradiotherapyandsurgeryisassociatedwithimprovedpathologicalresponsebutdoesnotaccuratelyestimatesurvivalinpatientswithresectableesophagealcancer
AT huyang longerintervalbetweenneoadjuvantchemoradiotherapyandsurgeryisassociatedwithimprovedpathologicalresponsebutdoesnotaccuratelyestimatesurvivalinpatientswithresectableesophagealcancer
AT yuanyong longerintervalbetweenneoadjuvantchemoradiotherapyandsurgeryisassociatedwithimprovedpathologicalresponsebutdoesnotaccuratelyestimatesurvivalinpatientswithresectableesophagealcancer
AT chenlongqi longerintervalbetweenneoadjuvantchemoradiotherapyandsurgeryisassociatedwithimprovedpathologicalresponsebutdoesnotaccuratelyestimatesurvivalinpatientswithresectableesophagealcancer
AT wangjin longerintervalbetweenneoadjuvantchemoradiotherapyandsurgeryisassociatedwithimprovedpathologicalresponsebutdoesnotaccuratelyestimatesurvivalinpatientswithresectableesophagealcancer
AT luyou longerintervalbetweenneoadjuvantchemoradiotherapyandsurgeryisassociatedwithimprovedpathologicalresponsebutdoesnotaccuratelyestimatesurvivalinpatientswithresectableesophagealcancer
AT liuyongmei longerintervalbetweenneoadjuvantchemoradiotherapyandsurgeryisassociatedwithimprovedpathologicalresponsebutdoesnotaccuratelyestimatesurvivalinpatientswithresectableesophagealcancer